摘要
β-淀粉样多肽(Aβ)聚积被认为是导致阿尔茨海默病(AD)病理变化的重要因素,而β-分泌酶(BACE1)是产生Aβ的限速酶。因此,以BACE1为靶标,抑制BACE1减少或阻断Aβ的生成已成为防治AD药物研究的热点,该文对近几年BACE1抑制剂的设计与进展进行简要的综述。
β-Amyloid peptide（Aβ） plays a central role in the pathophysiology of Alzheimer＇s desease（AD）.β- Amyloid cleaving enzyme-1 （BACE1, also called β-secretase）, which initiates the formation of Aβ, is an attractive target of discovering effective drug for treating AD. The evolution of design and development of BACE1 inhibitors in recent years were reviewed.
出处
《中国药物化学杂志》
CAS
CSCD
2006年第6期373-379,共7页
Chinese Journal of Medicinal Chemistry
